Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinic… Read more
Annovis Bio Inc (ANVS) - Net Assets
Latest net assets as of September 2025: $13.16 Million USD
Based on the latest financial reports, Annovis Bio Inc (ANVS) has net assets worth $13.16 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($17.19 Million) and total liabilities ($4.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $13.16 Million |
| % of Total Assets | 76.54% |
| Annual Growth Rate | 13.06% |
| 5-Year Change | 23.43% |
| 10-Year Change | -33.17% |
| Growth Volatility | 433.92 |
Annovis Bio Inc - Net Assets Trend (2009–2024)
This chart illustrates how Annovis Bio Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Annovis Bio Inc (2009–2024)
The table below shows the annual net assets of Annovis Bio Inc from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $9.31 Million | +220.09% |
| 2023-12-31 | $-7.75 Million | -127.37% |
| 2022-12-31 | $28.32 Million | -36.34% |
| 2021-12-31 | $44.49 Million | +490.04% |
| 2020-12-31 | $7.54 Million | +187.93% |
| 2019-12-31 | $-8.58 Million | -12.94% |
| 2018-12-31 | $-7.59 Million | -9.02% |
| 2017-12-31 | $-6.97 Million | -361.78% |
| 2012-12-31 | $2.66 Million | -80.89% |
| 2011-12-31 | $13.93 Million | -15.56% |
| 2010-12-31 | $16.49 Million | +1017.15% |
| 2009-12-31 | $1.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Annovis Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13411001400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.41K | 0.02% |
| Other Components | $144.16 Million | 1548.79% |
| Total Equity | $9.31 Million | 100.00% |
Annovis Bio Inc Competitors by Market Cap
The table below lists competitors of Annovis Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Equatorial Pará Distribuidora de Energia S.A
SA:EQPA3
|
$46.76 Million |
|
Shanghai Huili Building Materials Co Ltd
SHG:900939
|
$46.77 Million |
|
UNITED FOODBRANDS LIMITED
NSE:UFBL
|
$46.80 Million |
|
Harford Bank
PINK:HFBK
|
$46.82 Million |
|
Teleste Oyj
HE:TLT1V
|
$46.75 Million |
|
6934
TWO:6934
|
$46.75 Million |
|
Ta-Yuan Cogeneration Co Ltd
TWO:8931
|
$46.73 Million |
|
ASICLAND
KQ:445090
|
$46.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Annovis Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -7,750,846 to 9,307,646, a change of 17,058,492.
- Net loss of 24,590,375 reduced equity.
- New share issuances of 18,666,797 increased equity.
- Other factors increased equity by 22,982,070.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-24.59 Million | -264.2% |
| Share Issuances | $18.67 Million | +200.55% |
| Other Changes | $22.98 Million | +246.92% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Annovis Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.60x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-1.58 | $2.74 | x |
| 2018-12-31 | $-1.73 | $2.74 | x |
| 2019-12-31 | $-1.25 | $2.74 | x |
| 2020-12-31 | $1.20 | $2.74 | x |
| 2021-12-31 | $5.83 | $2.74 | x |
| 2022-12-31 | $3.47 | $2.74 | x |
| 2023-12-31 | $-0.86 | $2.74 | x |
| 2024-12-31 | $0.76 | $2.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Annovis Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -264.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.50x
- Recent ROE (-264.20%) is below the historical average (-69.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -25.03% | -2351.46% | 0.01x | 1.03x | $-517.22K |
| 2010 | -7.98% | -18.35% | 0.33x | 1.34x | $-2.96 Million |
| 2011 | -33.93% | 0.00% | 0.00x | 1.51x | $-6.12 Million |
| 2012 | -312.86% | -4495.62% | 0.07x | 1.07x | $-8.59 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $14.21K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $45.52K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-133.36K |
| 2020 | -72.43% | 0.00% | 0.00x | 1.08x | $-6.22 Million |
| 2021 | -32.56% | 0.00% | 0.00x | 1.03x | $-18.94 Million |
| 2022 | -88.78% | 0.00% | 0.00x | 1.27x | $-27.98 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-55.43 Million |
| 2024 | -264.20% | 0.00% | 0.00x | 1.50x | $-25.52 Million |
Industry Comparison
This section compares Annovis Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Annovis Bio Inc (ANVS) | $13.16 Million | -25.03% | 0.31x | $46.76 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |